Friday, July 10, 2026

pharma · Eczema · GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency

Hong Kong Baptist

Hong Kong Baptist is a pharma organization headquartered in CN. Primary therapeutic focus areas include Eczema, GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency, Infantile Colic, Feeding and Eating Disorders of C

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
18
Drugs
14
Patents
0
Clinical program

CKD-393 formulation I

Phase 1 · small molecule · Type II Diabetes

CKD-393 formulation I for Type II Diabetes is a Phase 1 program (small_molecule) at Hong Kong Baptist University with 1 ClinicalTrials.gov record(s).

← All Hong Kong Baptist University projects Phase 1 small molecule completed

Internal code A98_04BE2022P

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hong Kong Baptist University
Phase
Phase 1
Modality
small_molecule
Indication
Type II Diabetes
Status
completed
Trials
1

Clinical trials